Cellivery Expands Global Patent Scope for COVID-19 Immune Therapy iCP-NI... "Accelerating Commercialization"

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 18th that it is expanding the patent scope of the 'intrinsic immune control antiviral and anti-inflammatory COVID-19 immune therapeutic iCP-NI,' currently under development in the United States, from the U.S. to worldwide.

The patent includes the iCP-NI developed independently by Cellivery and the anti-inflammatory therapy using it. The accumulated research results so far were prepared and submitted by Dr. Earl Ruley of the Department of Pathology, Microbiology, and Immunology at Vanderbilt University School of Medicine in the U.S.

iCP-NI is a biopharmaceutical that controls the innate immune system to treat severe inflammation and sepsis. It is one of Cellivery's main pipeline products. It was developed to reduce the fatality of patients with severe symptoms and death caused by COVID-19 virus infection.

The person in charge of development at Cellivery explained, "So far, in a viral infection model with a 79% mortality rate, the mortality rate was only 16% when iCP-NI was administered, resulting in an 80% increase in survival rate, which is the key point," and added, "The global clinical research organization (CRO) Covance, which is conducting clinical development of iCP-NI in the U.S., evaluated that this is sufficient to submit to the U.S. Food and Drug Administration (FDA) as key efficacy results for clinical trials of COVID-19 therapeutics."

Daewoong Cho, CEO of Cellivery, said, "The patent scope includes that iCP-NI can be applied not only to COVID-19 infectious disease but also to severe inflammation and sepsis caused by pathogenic bacteria and various viral infections, as well as inflammation caused by trauma such as accidents, and many inflammatory diseases such as autoimmune diseases caused by environmental and genetic factors like atopic dermatitis."

This content was produced with the assistance of AI translation services.